Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis vaccines CMO joins Arterial

Dr Markus Weissbach becomes clinical trials director

Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its board.

Dr Weissback brings over 25 years of life science industry experience to the post - with particular expertise in cardiology, infectious diseases and oncology - and is currently chief operating officer at DS Biopharma in Dublin.

He recently served as chief medical officer at Novartis Vaccines and Diagnostics, and chief executive officer of Averion International.

Prior to this Weissbach was a director at Takeda Europe, with responsibility for its clinical research and development unit. He also brings expertise from Knoll, CytoTools Biotech, Vasopharm, Cardiorentis, BernaBiotech and Sunesis.

David Evans, director of Arterial, said: “The ability to convert strong science and supporting data into strong investor returns is what makes an outstanding private equity business.

“The addition of Markus to our team is fantastic news for investors and investees alike.”

21st February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....